このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions (POWERFUL)

2021年5月10日 更新者:Genesis Pharma S.A.

A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in Relapsed/ ReFractory Multiple Myeloma Patients Under Real-Life Conditions,

The importance of real-world evidence studies stems from the following considerations. The study population of a specific clinical trial needs to meet strict inclusion and exclusion criteria, which result in a population of participants that is not necessarily representative of the study population of interest treated in routine care. Furthermore, the outcomes of a clinical trial occur under controlled conditions that do not necessarily reflect the routine healthcare practice. This is especially true among patient populations with challenging to treat disease such as in MM, where personalized therapeutic approaches are commonly considered taking into consideration the patients' age and associated comorbidities, among other factors. In addition, observational studies, due to their non-interventional nature, often show increased degree of heterogeneity across the enrolled patient populations compared to clinical studies, thus aiding generalizability of the results.

In light of the above and due to the scarcity of evidence regarding the outcomes for patients with RRMM receiving Pom/LoDex in routine clinical practice, this retrospective chart review and prospective observational study aims to assess the PFS and response to treatment as well as to obtain real-world evidence on the utilization patterns and management strategy of Pom/LoDex in routine clinical care settings in Greece.

This is a non-interventional, multicenter, single-country, retrospective chart review and prospective cohort study which will include a representative sample of patients with RRMM who have been initiated on Pom/LoDex between 01 January 2016 and 28 February 2019 in the third line and beyond treatment setting under routine care conditions in Greece.

The study will be carried out by hospital-based hematology specialists practicing in geographically diverse locations throughout Greece and will be conducted under real-world conditions of daily clinical practice.

調査の概要

状態

完了

研究の種類

観察的

入学 (実際)

110

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Patra、ギリシャ
        • Ag.Andreas General Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

A total of 100 adult patients with RRMM who have been initiated on Pom/LoDex treatment as indicated in the product's Summary of Product Characteristics (SmPC) (i.e., after having received at least two prior therapies including both lenalidomide and bortezomib and whose disease progressed after the last treatment) between 01 January 2016 and 28 February 2019 and who are eligible for participation in the study according to the inclusion and exclusion criteria -as outlined in Section 10- are planned to be recruited in the present clinical study. For the justification of the sample size please refer to Section 13.1.

説明

  • Patients eligible for inclusion in this study have to meet all of the following criteria:

    • Adult subjects (aged ≥18 years) of either gender.
    • Subjects with a documented RRMM diagnosis according to IMWG or EBMT criteria prior to Pom/LoDex treatment.
    • Subjects who have been initiated on Pom/LoDex treatment as per the product's Summary of Product Characteristics (SmPC) between 01 January 2016 and 28 February 2019, after having received at least two prior therapies including both lenalidomide and bortezomib and whose disease progressed after the last treatment.*
    • Note: Retrospective patients who at the time of their enrollment in the study have already completed 3 or more cycles with Pom/LoDex must have available at least one post-baseline response assessment
    • Subjects with available medical files/records and detailed historical data on their disease course and clinical management.
    • Provision of signed informed consent form (ICF) for collecting and analyzing medical data pertinent to the objectives of this study.**

      • Note: For retrospective subjects who are deceased at the date of enrollment into the study a waiver of consent will be requested by the Hospital Scientific Committee and/or Administrative Board of each participating site to either implement a hospital ICF already in place or provide written approval of this study- specific waiver. In the occasion that waiver of consent is not granted by the Scientific Committee and/or Administrative Board of the study site, deceased subjects will not be enrolled in the study.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from participation in this study:

  • Prior malignancy (within the 3 years preceding initial diagnosis of MM).
  • Concurrent administration of anti-cancer regimens for malignancies other than MM.
  • Subjects currently participating or who have participated, during the treatment phase, in any investigational program with interventions outside of routine clinical practice.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Effectiveness of Pom/LoDex in terms of median PFS
時間枠:median time from start of Pom/LoDex treatment to disease progression or death, through study completion and maximum 50 months
To evaluate the effectiveness of Pom/LoDex in terms of median PFS, in eligible patients with RRMM in a real world setting in Greece.
median time from start of Pom/LoDex treatment to disease progression or death, through study completion and maximum 50 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Response to Pom/LoDex treatment in terms of ORR
時間枠:from start of Pom/LoDex until achievement of PR or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of ORR in the study RRMM population
from start of Pom/LoDex until achievement of PR or better, through study completion and maximum 50 months
Response to Pom/LoDex treatment in terms of CBR
時間枠:from start of Pom/LoDex until achievement of MR or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of clinical benefit rate (CBR) in the study RRMM population
from start of Pom/LoDex until achievement of MR or better, through study completion and maximum 50 months
Response to Pom/LoDex treatment in terms of DCR
時間枠:from start of Pom/LoDex until achievement of SD or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of disease control rate (DCR) in the study RRMM population
from start of Pom/LoDex until achievement of SD or better, through study completion and maximum 50 months
TTR among the RRMM study population who achieved at least partial response (PR)
時間枠:median from start of Pom/LoDex to first documented response (TTR), through study completion and maximum 50 months
To estimate time to response (TTR) to Pom/LoDex among the RRMM study population who achieved at least partial response (PR);
median from start of Pom/LoDex to first documented response (TTR), through study completion and maximum 50 months
DoR among the RRMM study population who achieved at least partial response (PR)
時間枠:median from start of Pom/LoDex to first disease progrestion or death (DoR), through study completion and maximum 50 months
To estimate duration of response (DoR) to Pom/LoDex among the RRMM study population who achieved at least partial response (PR);
median from start of Pom/LoDex to first disease progrestion or death (DoR), through study completion and maximum 50 months
12-month PFS rate
時間枠:time from start of Pom/LoDex until 12 months
To evaluate the 12-month PFS rate under treatment with Pom/LoDex in the RRMM study population
time from start of Pom/LoDex until 12 months
Time to progression
時間枠:median time from start of Pom/LoDex until disease progression or death, through study completion and maximum 50 months
To estimate time to progression (TTP) under treatment with Pom/LoDex in the RRMM study population
median time from start of Pom/LoDex until disease progression or death, through study completion and maximum 50 months
Real-world utilization patterns of Pom/LoDex in the RRMM study population
時間枠:no time frame - only proportion of patients in 12 month follow-up
To capture the real-world utilization patterns of Pom/LoDex in the RRMM study population, in terms of the rate of its incorporation in the third versus a later-line therapeutic strategy, and the prior treatment modalities employed in real-life clinical practice
no time frame - only proportion of patients in 12 month follow-up

その他の成果指標

結果測定
メジャーの説明
時間枠
Evaluate the effectiveness and response to Pom/LoDex treatment in the subpopulations of RRMM patients who have been initiated on Pom/LoDex in the third line versus later line setting
時間枠:from start of Pom/LoDex until 12 month follow-up
Separation of Pom/Dex treatment outcomes in two subgroups of patients (treated in the third line versus later lines)
from start of Pom/LoDex until 12 month follow-up
To evaluate the improvement of the QoR with Pom/LoDex continued treatment
時間枠:from start of Pom/LoDex until 12 month follow-up
To measure the improvement of the quality of response with Pom/LoDex continued treatment over time (i.e. improvement from PR to VGPR)
from start of Pom/LoDex until 12 month follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Kiki Karvounis、Genesis Pharma S.A.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年11月16日

一次修了 (実際)

2020年2月21日

研究の完了 (実際)

2020年2月28日

試験登録日

最初に提出

2017年10月31日

QC基準を満たした最初の提出物

2017年11月20日

最初の投稿 (実際)

2017年11月27日

学習記録の更新

投稿された最後の更新 (実際)

2021年5月12日

QC基準を満たした最後の更新が送信されました

2021年5月10日

最終確認日

2021年5月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する